| Ytd | -0.80% | |
| 1y | 78.37% |
| Open | 3.76 | Prev Close | 3.79 | Low | 3.69 | High | 3.80 | Mkt Cap | 337.56M |
| Vol | 201.14K | Avg Vol | 674.05K | EPS | 0.24 | P/E | 15.46 | Forward P/E | -1.56 |
| Beta | 0.64 | Short Ratio | 1.22 | Inst. Own | 34.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 3.75 | 200-d Avg | 3.81 | 1yr Est | 12.40 |
SABS News
AWM Investment Company Inc. purchased a new position in SAB Biotherapeutics, Inc. (NASDAQ: SABS) dur
SAB Biotherapeutics NASDAQ: SABS said its registrational Phase IIb SAFEGUARD trial of SAB-142 in new
Over 60 clinical sites activated in registrational SAFEGUARD study of SAB-142 in Stage 3 new onset t
Shares of SAB Biotherapeutics, Inc. (NASDAQ: SABS - Get Free Report) have earned a consensus rating
Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SA
MIAMI, July 07, 2026 (GLOBE NEWSWIRE) -- Breakthrough T1D, the leading global type 1 diabetes (T1D)
Barclays analyst Eliana Merle initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Over
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and rai
Top Wall Street analysts changed their outlook on top names. See all rating changes on our analyst r
Leerink Partners analyst Thomas Smith maintains SAB Biotherapeutics (NASDAQ:SABS) with a Outperfo
HC Wainwright & Co. analyst Emily Bodnar reiterates SAB Biotherapeutics (NASDAQ:SABS) with a
Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully h
Citigroup analyst Samantha Semenkow initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with
Wall Street analysts changed outlook on top names. See full ratings page for upgrades, downgrades, a
Jefferies analyst Roger Song initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy r
SAB Biotherapeutics NASDAQ: SABS said its lead type 1 diabetes candidate, SAB-142, remains on track
HC Wainwright & Co. analyst Emily Bodnar maintains SAB Biotherapeutics (NASDAQ:SABS) with a B
SAB Biotherapeutics (NASDAQ:SABS) reported quarterly losses of $(0.35) per share which missed the an
Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on tr
Rodman & Renshaw analyst Seema Sheoran reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Bu
MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage b
The executed agreement is valued at approximately $50 million, of which $36 million is contingent on
All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants
SAB Biotherapeutics is a clinical-stage biotech centered on SAB-142, a disease-modifying T1D candida
SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fu
MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage
MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage
SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a ful
MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage
HC Wainwright & Co. analyst Emily Bodnar maintains SAB Biotherapeutics (NASDAQ:SABS) with a B
T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Pha
Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Hall
Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollm
MIAMI, March 02, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage
SAB Biotherapeutics, Inc. (NASDAQ: SABS - Get Free Report) has received a consensus rating of "Moder
Viking Therapeutics (NASDAQ: VKTX - Get Free Report) and SAB Biotherapeutics (NASDAQ: SABS - Get Fre
MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage
UBS analyst Michael Yee initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating
Guggenheim analyst Yatin Suneja initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Bu
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and mai
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dos
SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing huma
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and mai
SAb Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing human